We send the latest information from SMC Laboratories.
Gilead Sciences, Inc. (USA) presented on August, 2020, the results of the phase 2b trial for NASH cirrhosis at…
Our clients presented data on treatment of NASH using STAMTM model at the EASL ~The Digital International Live…
Galectin Therapeutics (USA) announced on June 30, 2020, the commencement of patient enrolment of the adaptivel…
Terns Pharmaceuticals Inc. (USA and Shanghai) announced on 23 July, 2020, the initiation of patient dosing in …
SMC announces that NIDDK (MD) has published the results of a study using the STAMTM mouse model in Purinergic …
Genfit (France) announced on July 22, 2020, that it will discontinue Elafibranor's Phase 3 NASH clinical …
SMC announces that Merck & Co., Inc. (NJ) has published the results of a study using STAMTM mouse model in…
DURECT CORPORATION (USA) announced on May 26, 2020, that positive topline data was obtained in serum liver enz…
Intercept Pharmaceuticals, Inc. (USA) announced that it has received a notification from the FDA that it will …
Hepion pharma, which is our client, has announced the results of pharmacology study using a UUO mouse model. &…